Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas

Hiroyuki Orita, Yoshihiko Maehara, Hideaki Anai, Hideo Baba, Hiroki Kusumoto, Daisuke Korenaga, Keizo Sugimachi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalSeminars in Surgical Oncology
Volume10
Issue number2
DOIs
Publication statusPublished - Jan 1 1994

Fingerprint

Succinate Dehydrogenase
Anthracyclines
Stomach
Mitomycin
Carcinoma
Doxorubicin
Stomach Neoplasms
Aclarubicin
Neoplasms
Cisplatin
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Orita, H., Maehara, Y., Anai, H., Baba, H., Kusumoto, H., Korenaga, D., & Sugimachi, K. (1994). Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas. Seminars in Surgical Oncology, 10(2), 135-139. https://doi.org/10.1002/ssu.2980100215

Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas. / Orita, Hiroyuki; Maehara, Yoshihiko; Anai, Hideaki; Baba, Hideo; Kusumoto, Hiroki; Korenaga, Daisuke; Sugimachi, Keizo.

In: Seminars in Surgical Oncology, Vol. 10, No. 2, 01.01.1994, p. 135-139.

Research output: Contribution to journalArticle

Orita, H, Maehara, Y, Anai, H, Baba, H, Kusumoto, H, Korenaga, D & Sugimachi, K 1994, 'Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas', Seminars in Surgical Oncology, vol. 10, no. 2, pp. 135-139. https://doi.org/10.1002/ssu.2980100215
Orita, Hiroyuki ; Maehara, Yoshihiko ; Anai, Hideaki ; Baba, Hideo ; Kusumoto, Hiroki ; Korenaga, Daisuke ; Sugimachi, Keizo. / Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas. In: Seminars in Surgical Oncology. 1994 ; Vol. 10, No. 2. pp. 135-139.
@article{445ff24e469b428a820227e6aed49f68,
title = "Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas",
abstract = "In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75{\%} stained cells were scored as positive, and 14 of 58 cases (24{\%}) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2{\%} vs. 66.3 ± 16.1{\%} for Adriamycin (ADM), 75.5 ± 14.2{\%} vs. 59.1 ± 17.6{\%} for aclacinomycin A (ACR), 71.7 ± 15.0{\%} vs. 61.1 ± 14.0{\%} for mitomycin C (MMC), and 57.5 ± 18.4{\%} vs. 47.0 ± 16.7{\%} for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. {\circledC} 1994 Wiley‐Liss, Inc.",
author = "Hiroyuki Orita and Yoshihiko Maehara and Hideaki Anai and Hideo Baba and Hiroki Kusumoto and Daisuke Korenaga and Keizo Sugimachi",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/ssu.2980100215",
language = "English",
volume = "10",
pages = "135--139",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Expression of P‐glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas

AU - Orita, Hiroyuki

AU - Maehara, Yoshihiko

AU - Anai, Hideaki

AU - Baba, Hideo

AU - Kusumoto, Hiroki

AU - Korenaga, Daisuke

AU - Sugimachi, Keizo

PY - 1994/1/1

Y1 - 1994/1/1

N2 - In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.

AB - In 58 human gastric cancers, the expression of P‐glycoprotein (P‐gp) was evaluated immunohistochemically and chemosensitivity was determined using the in vitro succinate dehydrogenase inhibition (SDI) test. Tumors which contained over 75% stained cells were scored as positive, and 14 of 58 cases (24%) were positive. There was no significant correlation between P‐gp expression and clinicopathologic features. The succinate dehydrogenase (SD) activity for each drug of P‐gp positive and negative tumors was as follows: 81.8 ± 15.2% vs. 66.3 ± 16.1% for Adriamycin (ADM), 75.5 ± 14.2% vs. 59.1 ± 17.6% for aclacinomycin A (ACR), 71.7 ± 15.0% vs. 61.1 ± 14.0% for mitomycin C (MMC), and 57.5 ± 18.4% vs. 47.0 ± 16.7% for cisplatin (CDDP). The increase in SD activity was evident in P‐gp positive tumors compared with negative ones in cases of ADM (P = 0.0044), ACR (P = 0.0105), and MMC (P = 0.0353). We suggested that P‐gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. © 1994 Wiley‐Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0028355797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028355797&partnerID=8YFLogxK

U2 - 10.1002/ssu.2980100215

DO - 10.1002/ssu.2980100215

M3 - Article

C2 - 7914378

AN - SCOPUS:0028355797

VL - 10

SP - 135

EP - 139

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -